EMA Authorised: Xolremdi (mavorixafor) — Norgine B.V.

View source ↗

Summary

EMA authorised Xolremdi (mavorixafor) by Norgine B.V. for primary immunodeficiency diseases (orphan medicine).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• XOLREMDI (mavorixafor)

Snippet

Status: Authorised. Therapeutic area: Primary Immunodeficiency Diseases. MAH: Norgine B.V.. Decision date: 03/07/2026. Orphan medicine